Eli Lilly and Company (NYSE:LLY) Shares Unloaded Sen. Ron Wyden

Senator Ron Wyden (D-Oregon) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had sold between $50,001 and $100,000 in Eli Lilly and Company stock on February 10th.

Senator Ron Wyden also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of iRobot (NASDAQ:IRBT) on 2/6/2025.
• Sold $1,001 – $15,000 in shares of Solventum (NYSE:SOLV) on 2/6/2025.
• Purchased $50,001 – $100,000 in shares of Eli Lilly and Company (NYSE:LLY) on 1/22/2025.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $874.12 on Friday. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a market capitalization of $829.82 billion, a price-to-earnings ratio of 74.65, a price-to-earnings-growth ratio of 1.39 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm’s fifty day moving average price is $801.33 and its 200 day moving average price is $846.75.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its board has initiated a stock buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 51.24%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on LLY shares. Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Citigroup dropped their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Barclays lowered their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds have recently made changes to their positions in the business. AMF Tjanstepension AB boosted its position in Eli Lilly and Company by 113.7% during the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock worth $293,964,000 after acquiring an additional 176,552 shares during the period. Values Added Financial LLC lifted its holdings in Eli Lilly and Company by 4.9% in the third quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after purchasing an additional 17 shares during the period. GAM Holding AG lifted its holdings in Eli Lilly and Company by 55.3% in the third quarter. GAM Holding AG now owns 29,978 shares of the company’s stock worth $26,559,000 after purchasing an additional 10,677 shares during the period. Liberty Capital Management Inc. lifted its holdings in Eli Lilly and Company by 5.7% in the third quarter. Liberty Capital Management Inc. now owns 2,150 shares of the company’s stock worth $1,905,000 after purchasing an additional 115 shares during the period. Finally, Global X Japan Co. Ltd. lifted its stake in shares of Eli Lilly and Company by 10.6% in the 3rd quarter. Global X Japan Co. Ltd. now owns 2,614 shares of the company’s stock worth $2,316,000 after acquiring an additional 251 shares during the period. Institutional investors own 82.53% of the company’s stock.

About Senator Wyden

Ron Wyden (Democratic Party) is a member of the U.S. Senate from Oregon. He assumed office on January 30, 1996. His current term ends on January 3, 2029. Wyden (Democratic Party, Independent Party) ran for re-election to the U.S. Senate to represent Oregon. He won in the general election on November 8, 2022. He advanced from the Democratic primary on May 17, 2022. In 2018, the Town Hall Project, which described itself as “a citizen powered, grassroots effort that empowers constituents across the country to have face-to-face conversations with their elected representatives,” named Wyden town hall MVP for the second year in a row. According to OregonLive, Wyden held over 900 town hall meetings between 1996 and 2018. Wyden previously served in the U.S. House of Representatives, representing Oregon’s 3rd Congressional District from 1981 to 1996. As of a 2014 analysis of multiple outside rankings, Wyden is an average Democratic member of Congress, meaning he will vote with the Democratic Party on the majority of bills.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.